Trials / Conditions / Refractory High Grade B-Cell Lymphoma

Refractory High Grade B-Cell Lymphoma

15 registered clinical trials studyying Refractory High Grade B-Cell Lymphoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lym NCT07098364	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726	University of Washington	Phase 2
Recruiting	Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527	AIDS Malignancy Consortium	Phase 1
Terminated	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376	Roswell Park Cancer Institute	Phase 1
Recruiting	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse NCT06271057	The Lymphoma Academic Research Organisation	Phase 2
Recruiting	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymp NCT05672251	City of Hope Medical Center	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2
Recruiting	Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088	Sumithira Vasu	Phase 1
Active Not Recruiting	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy NCT05075603	NeoImmuneTech	Phase 1
Completed	Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma NCT04432506	M.D. Anderson Cancer Center	Phase 2
Completed	Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy NCT04409314	University of California, San Francisco	—
Unknown	Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Wit NCT04870853	M.D. Anderson Cancer Center	—
Terminated	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients Wit NCT04205838	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma NCT03309878	National Cancer Institute (NCI)	Phase 1 / Phase 2